| DIRECT COMPETITOR COMPARISON | |
| WX | CRL | CVD | ICLR | Industry | | Market Cap: | 1.16B | 2.14B | 3.26B | 1.29B | 123.65M | | Employees: | 4,135 | 9,000 | 8,826 | 7,000 | 181 | | Qtrly Rev Growth (yoy): | 3.80% | -13.10% | 5.60% | -2.30% | 14.60% | | Revenue (ttm): | 260.59M | 1.22B | 1.92B | 880.29M | 31.21M | | Gross Margin (ttm): | 38.16% | 36.22% | 30.66% | 43.02% | 72.61% | | EBITDA (ttm): | 85.76M | 284.53M | 324.37M | 143.58M | -1.65M | | Oper Margins (ttm): | 16.25% | 15.76% | 12.45% | 12.85% | 2.37% | | Net Income (ttm): | -8.31M | -567.54M | 180.02M | 84.45M | N/A | | EPS (ttm): | -0.789 | -8.569 | 2.808 | 1.430 | N/A | | P/E (ttm): | N/A | N/A | 18.16 | 15.33 | 14.06 | | PEG (5 yr expected): | 2.37 | 1.59 | 1.41 | 0.91 | 2.21 | | P/S (ttm): | 4.47 | 1.76 | 1.71 | 1.46 | 3.31 |
|
| CRL = Charles River Laboratories International Inc. | | CVD = Covance Inc. | | ICLR = ICON plc | | Industry = Drug Manufacturers - Major | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.09 | -0.69% | 56.77B | 12.23 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 48.13 | -0.35% | 13.92B | 16.11 | | Genzyme Corp. | GENZ | 49.60 | -0.24% | 13.16B | 28.28 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.355 | -0.57% | 41.72B | 17.93 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.31 | -0.61% | 8.97B | 1026.73 | | Teva Pharmaceutical Industries Limited | TEVA | 52.90 | -0.66% | 46.60B | 48.40 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.87 | -0.16% | 4.02B | 19.52 | | King Pharmaceuticals Inc. | KG | 11.40 | -1.04% | 2.83B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.28 | 0.55% | 5.59B | 112.15 | | Pfizer Inc. | PFE | 17.90 | -0.89% | 144.44B | 14.87 | | Johnson & Johnson | JNJ | 64.25 | -0.19% | 177.27B | 14.03 | | GlaxoSmithKline plc | GSK | 42.16 | -1.13% | 106.88B | 13.30 | | Sanofi-Aventis | SNY | 38.69 | -0.23% | 101.02B | N/A | | Novartis AG | NVS | 55.26 | -0.43% | 125.51B | 16.54 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 40.96 | -0.97% | N/A | N/A | | AstraZeneca plc | AZN | 45.61 | -1.13% | 66.13B | 9.16 | | Abbott Laboratories | ABT | 53.2501 | -0.76% | 82.36B | 14.43 | | Bristol-Myers Squibb Co. | BMY | 25.15 | -0.51% | 49.82B | 13.01 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | ICLR | | ICON Announces Details of New Translational Medicine Unit in Manchester
Mon 5:21am -
Business Wire | | • | ICLR | | ICON Receives Warning Letter Relating to Two Studies
Fri, Dec 4 -
Business Wire | | • | CVD | | 5-Star Stocks on the Upswing
Wed, Dec 2 -
at Motley Fool | | • | CVD | | Covance to Establish a New Nutritional Chemistry and Food Safety Laboratory in Battle Creek, Michigan
Tue, Dec 1 -
PR Newswire | | • | CVD | | Covance to Present at Piper Jaffray 21st Annual Health Care Conference
Mon, Nov 30 -
PR Newswire | | • | CRL | | Zacks #5 Rank Additions for Friday
Fri, Nov 27 -
Zacks.com | | • | CRL | | We Expect Ailing CROs to Recover
Wed, Nov 25 -
Morningstar.com | | • | CRL | | Zacks #5 Rank Additions for Tuesday
Tue, Nov 24 -
Zacks.com | | • | CRL | | China Biotech Week in Review: CROs Consolidating
Sun, Nov 22 -
at Seeking Alpha | | • | CVD | | The Stockpickers: Fund managers hunt small-caps that can grow bigger
Fri, Nov 20 -
at MarketWatch | | • | ICLR | | Icon Enters Oversold Territory
Tue, Nov 17 -
Zacks.com | | • | CRL | | Healthcare Bill Will Be Law By New Year Says Morningstar Strategist
Mon, Nov 9 -
Wall Street Transcript | | • | CRL | | Bearish MACD for Charles River
Mon, Nov 9 -
Zacks.com | | • | CRL | | Charles River downgraded by Barclays Capital
Mon, Nov 9 -
Briefing.com | | • | CRL | | Zacks #5 Rank Additions for Monday
Mon, Nov 9 -
Zacks.com | | • | CRL | | CHARLES RIVER LABORATORIES INTERNATIONAL INC Financials
Sat, Nov 7 -
EDGAR Online Financials | | • | CRL | | [$$] Garmin Gets Lost As Merck Rises 6.4%
Thu, Nov 5 -
at The Wall Street Journal Online | | • | ICLR | | CFO Interview: BioPharm Asia, Inc. - Michael Guo
Mon, Nov 2 -
Wall Street Transcript | | • | ICLR | | ICON Selected by Lilly to Oversee its Clinical Data Management in Japan
Mon, Nov 2 -
Business Wire | | | All Headlines for these symbols... |
|
|
|
0.89% Nasdaq 
Competitors
